Genomic Health (GHDX) Prostate Test Shows Encouraging Signs - Analyst

June 18, 2013 9:53 AM EDT Send to a Friend
Get Alerts GHDX Hot Sheet
Price: $32.33 +4.02%

Rating Summary:
    6 Buy, 7 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 19 | New: 16
Trade GHDX Now!
Join SI Premium – FREE
Leerink Swann today maintained an Outperform rating on Genomic Health Inc. (NASDAQ: GHDX) with a price target of $41.00. Analyst Dan Leonard noted early signs of prostate test adoption.

"We came away marginally more encouraged on early adoption of GHDX's prostate cancer test following recent conversations with two MEDACorp urologists. While many clinical questions remain, we continue to see some upside to our prostate test volume expectations for GHDX," said Leonard. "While the two urologists generally had mixed views of the test's utility (one was more positive than the other), both had already ordered the test for some of their patients."

"Our conversations further reinforced our view that there is appetite in the urology community to augment the current clinical decision process when determining which patients are candidates for active surveillance vs. otherwise," added the analyst.

For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on Genomic Health Inc. click here.

Shares of Genomic Health Inc. closed at $32.97 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment